Recombinant Factor VIIa to Successfully Manage Disseminated Intravascular Coagulation From Amniotic Fluid Embolism
- 1 February 2007
- journal article
- case report
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 109 (2), 524-525
- https://doi.org/10.1097/01.aog.0000235711.11817.8c
Abstract
Amniotic fluid embolism (AFE) is a rare syndrome that can complicate pregnancy and labor. It often has debilitating and lethal consequences. One serious sequela of AFE is disseminated intravascular coagulation (DIC). This report describes an atypical presentation of AFE manifested by sudden fetal bradycardia and complicated by maternal DIC. The DIC was eventually successfully treated with the use of recombinant activated factor VIIa. The use of recombinant activated factor VIIa in cases of massive hemorrhage, such as in our patient, is controversial but has been shown, in some cases, to reverse DIC and be successful. The use of recombinant activated factor VIIa should be considered in patients with massive obstetric hemorrhage in whom standard measures of stabilization are unsuccessful.Keywords
This publication has 7 references indexed in Scilit:
- Thromboembolic Adverse Events After Use of Recombinant Human Coagulation Factor VIIaJAMA, 2006
- Recombinant factor VIIa after amniotic fluid embolism and disseminated intravascular coagulopathyInternational Journal of Gynecology & Obstetrics, 2004
- ‘Last‐ditch’ use of recombinant factor VIIa in patients with massive haemorrhage is ineffectiveVox Sanguinis, 2004
- Recombinant Factor VIIa in the Treatment of BleedingAmerican Journal of Clinical Pathology, 2004
- The Obstetric Patient and Disseminated Intravascular CoagulationClinics in Perinatology, 1986
- MATERNAL PULMONARY EMBOLISM BY AMNIOTIC FLUIDJAMA, 1941